Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 3;19(3):1753.
doi: 10.3390/ijerph19031753.

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis

Affiliations

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis

Jaime Fernández-Bravo-Rodrigo et al. Int J Environ Res Public Health. .

Abstract

Background: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients.

Methods: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP.

Results: The findings of this study will be reported in a peer-reviewed journal.

Conclusions: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.

Keywords: calcitonin gene-related peptide (CGRP); eptinezumab; erenumab; fremanezumab; galcanezumab; meta-analysis; migraine prevention; monoclonal antibodies; protocol; review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of identification, screening, eligibility and inclusion of studies.

Similar articles

Cited by

References

    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. doi: 10.1177/0333102417738202. - DOI - PubMed
    1. Charles A. The pathophysiology of migraine: Implications for clinical management. Lancet Neurol. 2018;17:174–182. doi: 10.1016/S1474-4422(17)30435-0. - DOI - PubMed
    1. Buse D.C., Greisman J.D., Baigi K., Lipton R.B. Migraine Progression: A Systematic Review. Headache. 2019;59:306–338. doi: 10.1111/head.13459. - DOI - PubMed
    1. Borkum J.M. Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis. Headache. 2016;56:12–35. doi: 10.1111/head.12725. - DOI - PubMed
    1. Pescador Ruschel M.A., De Jesus O. Migraine Headache. StatPearls Publishing; Treasure Island, FL, USA: 2021.

Publication types

MeSH terms

Substances